Eli Lilly and Company

Ligand Pharmaceuticals, Inc.

David Andrew Neel

John H McDonald, Iii

Donald Paul Matthews

Thomas Alan Crowell

Michael Gregory Bell

Mark Alan Winter

Anthony John Shuker

Christopher J Rito

Cynthia Darshini Jesudason

Michael R Jirousek

Margaret Mary Faul

Christine Ann Droste

Jon Kevin Reel

J Jeffry Howbert

Timothy A Grese

Karen Lynn Lobb

Prabhakar Kondaji Jadhav

Beverley Greenwood

Raymond F Brown

Marcus F Boehm

Mitchell I Steinberg

Pierre-Yves Michellys

Edward C R Smith

Kevin Matthew Gardinier

Peter Ambrose Lander

Jonathan Edward Green

Douglas Linn Gernert

Kevin Robert Fales

Christopher M Mapes

Matthew Lee Brown

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I). 

Tetrahydrocarbazole derivatives useful as androgen receptor modulators

The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Retinoid X receptor modulators

The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure, comprising administering to a patient in need thereof an effective amount of a compound of the formula: I or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I 

Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:

Selective &bgr;3 adrenergic agonists

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##

Selective .beta.-3 adrenergic agonists

Selective .beta..sub.3 adrenergic agonists

The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.

Selective .beta.3 adrenergic agonists

The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometalic-3-indole in the presence of a transition metal catalyst.

Synthesis of indolymaleimides

The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.

Synthesis of indolylmaleimides

Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.

Pyrazolidinone CCK and gastrin antagonists and pharmaceutical

Growing community of inventors

Zionsville, IN, United States of America

David Andrew Neel